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Abstract 
Diabetes is a growing concern world wide. Ideal management of the disease requires 
extensive self-care and broad follow-up by health care professionals. Considerable research 
has been done on involving the pharmacist in the healthcare of patients with diabetes, arguing 
that community pharmacists’ high availability to patients and specialized medication-focused 
education makes them a valuable asset to the diabetes team.  
This thesis consists of four papers. The work for these papers was performed from 2004 to 
2009. Paper I gives an overview over diabetes care provided by Norwegian pharmacies. It is 
based on a descriptive study where all Norwegian pharmacies were invited to participate by 
filling out an online questionnaire. We found that most pharmacists were interested in 
working diabetes services. Some pharmacies offered diabetes patients a wide range of 
services, but quality control of these services was seldom established. Almost all pharmacies 
offered practical services related to self-monitoring of blood glucose (SMBG), while giving 
advice on diet and other lifestyle factors was rarely done. The pharmacists were motivated to 
work within diabetes care, in particular SMBG. In Paper II we demonstrate how one can 
assure the quality of a point-of-care test (POCT) at the community pharmacy, in our case a 
blood glucose test, and show that when given the correct follow-up the pharmacies are able to 
match the quality of the results achieved at general practitioners’ offices. In Paper III we 
tested a new pharmacy service, where patients brought their own glucometers to the 
pharmacies where the glucose method was established. Patients had both their performance 
and their glucometer tested against the pharmacy method. We found that this reduced the 
number of user errors. It had no effect on the analytical quality of the patients’ SMBG results, 
which was good throughout the study. The patients’ trust in their own measurements 
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increased after their visit to the pharmacy, and the patients expressed a wish for annual 
pharmacy controls.   
In Paper IV we report the sales of SMBG strips to all non-institutionalized patients in Norway 
in 2008. We found that 96 999 different patients purchased strips that year. This gave a 
prevalence of 2 % in the Norwegian population, and approximately 70 % among patients 
being treated pharmacologically for their diabetes. The mean number of strips per day was 
1.7, however 53 % of the patients did not purchase enough strips to monitor their blood 
glucose daily. The one percent of the patients who bought the most strips was responsible for 
8 % of the costs. Most patients used only one brand of glucometer, though three percent 
purchased from 3-7 different types of strips. Use of strips increased with number of different 
types of strips.  
The sum of this work suggests that Norwegian pharmacies can be more actively used in 
assisting diabetes patients with their SMBG. The employees are motivated, and already 
involved at a smaller scale. Given correct training and follow-up they are capable of 
performing services involving POCT of good analytical quality, and patients are happy to 
receive this type of service from their community pharmacy. A small number of patients use a 
disproportionate amount of resources spent on SMBG, while a large number of patients rarely 
perform SMBG, giving room for improvement in the way resources are being spent. Several 
challenges remain: reaching the patients most in need of SMBG assistance, attaining access 
for pharmacies to the quality control support from the Norwegian Quality Improvement of 
Primary Care Laboratories (NOKLUS), and ensuring remuneration for the service. 
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Background 
Diabetes Mellitus is a disorder of the carbohydrate metabolism, caused by a combination of 
hereditary and environmental factors and characterized by hyperglycaemia resulting from 
inadequate secretion and/or utilisation of insulin. The chronic hyperglycaemia of diabetes 
leads to long term microvascular complications in the form of retinopathy, nephropathy and 
neuropathy as well as a heightened risk for the macrovascular diseases myocardial infarction, 
stroke and angina.1;2 The two main forms of diabetes mellitus are type 1 diabetes, 
characterized by -cell destruction leading to total insulin deficiency, and type 2 diabetes, 
defined by insulin resistance and a relative insulin deficiency. The World Health Organization 
(WHO) estimates that more than 220 million people worldwide have diabetes3, 90 % of these 
have type 2 diabetes.3 Due to the world wide increase in the proportion of people > 65 years 
of age combined with a rise in other risk factors such as obesity and sedentary lifestyle this 
figure is growing fast,4;5 and is likely to more than double by 2030.3;5 The Norwegian 
Diabetes Association (NDA) estimates that 375,000 people, 7.7 % of the population, have 
diabetes in Norway, and that approximately half of them have yet to be diagnosed.6 This 
concurs well with the numbers from the Norwegian national prescription database (NorPD), 
that registered 131,922 people collecting at least one prescription for antidiabetics during 
2007, corresponding to a diagnosed diabetes prevalence of 2.8 %.7 This number does not 
include patients with type 2 diabetes treated with diet only. Diabetes mellitus can now be 
considered a pandemic, and the human and economic costs of the disease will continue to 
rise.3  
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Management of diabetes 
Due to the many possible complications and co-morbidities of diabetes and the complexity of 
the disease itself, establishing and maintaining an optimal treatment is challenging for both 
the patients and for the healthcare professionals helping them. Strict glycemic control, aimed 
at maintaining blood glucose concentrations close to the normal range (preprandial capillary 
plasma glucose 3.9 – 7.2 mmol/L and postprandial plasma glucose <10 mmol/L8) has been 
considered the optimal treatment goal for patients with both type 1 and type 2 diabetes since 
the American Diabetes Control and Complications Trial (DCCT, 1993)9 and the UK 
Prospective Diabetes Study (UKPDS, 1998)10-12 showed that this reduces both microvascular 
and macrovascular complications of diabetes.9-13 With the exception of the recently published 
ACCORD study that reported an increased mortality in patients in intensive therapy to target 
normal glycated haemoglobin levels,14 later studies have confirmed the benefit of strict 
glycemic control.13;15-17 In addition it is recognized that strict blood pressure control and 
cholesterol lowering treatment with statins reduces microvascular endpoints and diabetes 
related deaths in patients with type 2 diabetes.18-20 As a result diabetes patients are often 
prescribed a long list of drugs, which may introduce new challenges such as drug interactions, 
adverse effects, contraindications and adherence-issues.21-25 To avoid serious long-term 
complications such as blindness and amputations regular controls of eyes and feet are 
recommended, adding to the management burden of patients and healthcare professionals. 
Investigating the best way to manage diabetes care has been the focus of many studies. The 
Cochrane group did a review on this topic in 2000 concluding that “multifaceted professional 
interventions can enhance the performance of health professionals in managing patients with 
diabetes”.26 Considering the complex nature of insulin treatment and the complex drug regime 
of many type 2 diabetes patients, pharmacists, with their specialist knowledge on drugs and 
drug usage, could be a valuable member of such a multidisciplinary team.27-30   
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Self-monitoring of blood glucose (SMBG) 
History and recommendations 
As early as 1776 the physician Mathew Dobson documented that both urine and blood from a 
patient with diabetes contained sugar, and in 1815 the French chemist Chevreul demonstrated 
that the exact compound was glucose. After this clinical tests for glucose emerged alongside 
physiological studies, and in 1890 researchers found that removing the pancreas resulted in 
diabetes. While the early tests for glucose in blood required large volumes, micromethods 
soon evolved.31 Self-sampling for blood glucose determination was introduced by Keen and 
Knight in 1962,32 a colorimetric method where the sample was obtained by the patient at 
home, but the analysis was performed at a laboratory. Soon after, in 1964, a method using an 
enzyme test strip was presented.33 The first studies to establish the use of self-monitoring of 
blood glucose (SMBG) and show an effect on glycemic control was published in 1978, when 
two studies, published in the same volume of Lancet, described the results of 69 and 64 
patients respectively, using two different instruments for self-monitoring.34;35 That SMBG 
could improve and maintain glycemic control without increasing the frequency of 
hypoglycaemia lead to the implementation of SMBG in routine care.31 The role of SMBG in 
the treatment of diabetes is still widely debated, as it has proved difficult to isolate and 
measure its effects.36-44 Monitoring alone does not affect clinical endpoints; improved health 
outcomes rely on the patients adjusting therapy, diet or exercise based on the results they 
obtain.45 While there is a general consensus that SMBG should be used by patients treated 
with insulin46 who risk hypoglycaemic incidents and can use their blood glucose results to 
regulate their treatment,47;48 there is disagreement on its place in the treatment of patients with 
type 2 diabetes not being treated with insulin.39;42;45;49-54 Still, many guidelines recommend the 
use of SMBG to all diabetes patients as useful in achieving glycemic goals.8;55-57  
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Technology and chemistry of SMBG 
The current glucometers are two- part systems, consisting of the meter itself and a test strip. 
The glucometer is a biosensor, where the enzyme-containing single-use test strip is the 
biological recognition element where the blood sample is applied and the reaction takes place. 
The meter itself is the physico-chemical transducer, and is either an electrochemical or an 
optical device that “reads” the strip and converts its signal to a digital value, which is then 
shown in a display (see Figure 1). 
Figure 1. Schematic overview of a glucometer and strip (biosensor). Glucose in the blood 
sample diffuses through the membrane barrier and reacts with enzymes imbedded in the test 
strips. The resulting electrons (the biodetection agent) are “read” by the transducer that 
converts the information into a quantifiable electrical signal. The signal is then displayed in a 
conventional format (such as mmol/L). (Figure adopted from Rosen58).
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Biosensors are simple to use devices that do not require sample preparation but can be used 
directly on native test material, in this instance whole blood. The strips rely on enzymatic 
processes were glucose is oxidized, and the resulting electrons used to reduce a mediator 
molecule, typically a small organic or inorganic compound capable of existing in both a 
reduced and an oxidized form. The mediator molecule then delivers the electrons to either an 
electrode (in an electrochemical method) or to an indicator molecule that forms colour and 
can be read by a photometer.58-60   
Different systems use different oxidoreductases to oxidize glucose. The most common are 
glucose oxidase (GOD) and different types of glucose dehydrogenase (GDH). All enzymes 
use coenzymes such as flavin adenine dinucleotide, pyrrolo quinoline quinine or nicotinamide 
adenine dinuclotide, and some processes may also rely on additional enzymes such as 
peroxidase where the overall reaction involves intermediate steps. The method used in many 
laboratories, a combination of hexokinase and glucose-6-phosphate dehydrogenase, is not 
used in current test strips.61  
Accuracy and precision of SMBG 
Accuracy is defined as “closeness of agreement between a measured quantity value and a true 
quantity value of a measurand.”62 The term “accuracy”, when applied to a set of test results, 
involves a combination of random error components and a common systematic error or bias 
component.63  If one measures the closeness of agreement between the average value obtained 
from a large series of test results and an accepted reference value, thereby eliminating the 
contribution of random error, the term used is trueness.62 Trueness is usually expressed in 
terms of its inverse, bias.63 Bias is caused by systematic error, for example wrong calibration, 
wrong storage of reagents, and lack of user education.64 Precision of measurement is 
“closeness of agreement between (…) measured quantity values obtained by replicate 
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measurements on the same or similar objects under specified conditions. The degree of 
precision is expressed numerically by the statistical measures of imprecision of 
measurements, such as standard deviation and coefficient of variation, that are inversely 
related to precision”.62;63 Imprecision is the result of random error, such as varying quality of 
the equipment, varying measurement technique (test preparation, timing), or lack of user 
education.64  Figure 2 shows the relationships between the different types of error, qualitative 
performance characteristics and their quantitative expression.65
Figure 2. Relationships between types of error, qualitative performance characteristics and 
their quantitative expression. (Figure adopted from Menditto65).
There is no standardized approach for evaluating the analytical performance of SMBG 
instruments, though several professional recommendations exist.55;63;66;67 Two commonly 
used quality specifications for SMBG devices are the Clarke error grid analysis (EGA), 
published by Clarke et al in 1987,68 and ISO 15197, published by the International 
Organization for Standardization.63 The EGA is used to assess the clinical significance of 
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differences between the glucometer in question and a reference measurement, often described 
as the glucometers clinical accuracy,68 though actually it describes potential consequence of 
the patient’s actions based on his results.69  Measurements of the glucometer in question are 
compared to a reference value, by plotting the results of each measurement into different 
zones drawn on the grid (Figure 3). 
Figure 3. The Clarke Error Grid. Region A are values within 20% of the reference sensor, 
Region B contains points that are outside of 20% but would not lead to inappropriate 
treatment, Region C are points leading to unnecessary treatment, Region D are points 
indicating a potentially dangerous failure to detect hypo- or hyperglycemia, and Region E are 
points that would confuse treatment of hypoglycemia for hyperglycemia and vice-versa. 
(Clarke68).
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The grid breaks down a scatterplot of a reference method and an evaluated glucometer into 
five regions. Critics of the method have claimed that the grid has “arbitrary” regions that 
should be updated,69;70 (and this has been done by Parkes in the Parkes Error Grid, also known 
as the  Consensus Error Grid or the Becton Dickinson (BD) Error Grid 70) and that it is not 
precise enough due to the use of broad regions.69 Both critics and authors agree that the grid 
should not be used alone, but rather as an addition to other statistical methods of assessing 
accuracy.69;71  
ISO 15197, the specification used in this thesis, states that 95 % of the individual glucose 
results shall fall within ± 0.83 mmol/L of the results of a reference glucose method at glucose 
concentrations < 4.2 mmol/L and within ± 20 % at glucose concentrations   4.2 mmol/L.63
While this standard dictates a procedure for quality evaluation for manufacturers, there are no 
standard procedures for how to perform quality control of SMBG devices that are in use by 
patients.72 To obtain realistic measures of accuracy and precision it is important to test devices 
in the hands of the patients8;72 as these results may often differ from results of measurements 
performed by professionals.73;74  We know very little about the accuracy of measurements 
performed by patients in daily life, and throughout the lifetime of the device.72 Control 
material, a “specimen, or solution, which is analyzed solely for quality control purposes",75 is 
sold by many manufacturers to be used with their instruments, though few patients use this 
regularly.73 However it is important to be aware of the limitations of control material. The 
material does not come with a “true value”, but rather a glucose interval that the result should 
lie within. This means that the control material may be suited for an internal control of 
instrument precision; however it does not give an accurate representation of the instruments 
trueness. An additional problem is that instrument performance using control material is not 
necessarily transferrable to the performance of the instrument when measuring blood.76-78   
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External quality assessment (EQA) can be used to evaluate the quality of glucose 
measurements, both those performed by health personnel and SMBG performed by patients. 
In an EQA the patient or professional receives control material, preferably of the same origin 
as patient samples, analyses it and returns the result to the EQA agency. As SMBG and POCT 
devices for glucose utilize whole blood, this is the preferred control material. However in 
such a sample ongoing glycolysis will reduce the glucose concentration by 5-7 % per hour at 
room temperature, and as EQA material is not analysed immediately, the control material 
must be stabilized. As the preservatives added to the sample may affect different instruments 
in different ways, a method specific target value is assigned to the control material based on a 
median of all participants using a certain instrument. Each participant is then given feedback 
on how they performed compared to the target value and other participants; however this 
means that only relative trueness, the deviation from the method specific target value, is 
assessed. 
Another method for quality control of SMBG is using a split sample design79-82 where the 
patients’ performance is monitored and the results are compared to a “true value” ideally 
obtained by a “reference method”. This method has advantages compared to conventional 
EQA since the patients’ performances can be observed and it is therefore possible to detect 
user errors. Also, the use of native blood makes it possible to compare the performance of 
different instruments.
Many patients, and perhaps also health professionals, are not aware that the digital number 
provided by their glucometer might not be the exact value.72 However knowledge of the 
uncertainty imbedded in the value, e.g. that a displayed value of 4 mmol/L may in fact imply 
a true result lying between 3.2 and 4.8 mmol/L, is important in order to achieve a realistic 
understanding of SMBG and its uses. 
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Sources of error of SMBG  
User error 
Among patients and healthcare workers alike many may consider SMBG a mundane task; 
however there are many steps that must be performed correctly in order to obtain a reliable 
result. These are sequential in nature, meaning that each step is reliant on the success of the 
previous step. When investigating the user-friendliness of a SMBG system that advertised that 
it “measured blood glucose in three easy steps”, Rogers et al identified 52 sub-steps that the 
user must perform, from the set up of the meter (6 steps) and checking the system (22 steps), 
to testing of blood glucose (24 steps).83 Manufacturers strive to make devices increasingly 
user-friendly through eliminating the necessity of manual coding, reducing the required 
amount of blood and outfitting the devices with alarms that warn the user of under-filled 
strips. Still user error is among the most common reasons for faulty results.72;73;84 In an 
evaluation of 9 different SMBG instruments 2 % to 34 % of patients (depending on the 
instrument) responded that they had technical difficulties with the instrument.85  
Müller et al86 classifies potential errors in 5 categories according to their potential effect on 
the patient or the results of the measurement (Table 1). Table 2 shows a list of possible 
sources of user error categorized in Müller’s 5 error codes.86  Not all user errors will 
necessarily lead to erroneous results, but may instead make it difficult to utilize the results 
optimally (for example not saving/documenting the results of a measurement), or may lead to 
a more painful measurement for the patient, thereby lessening compliance (for example not 
changing the lancet with every measurement). Assessing user technique is therefore important 
also when the analytical quality of the measurement seems satisfactory.  
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Table 1. Classification of potential errors in conducting blood glucose tests. (Müller et 
al.86)
Error 
Code
Error Category Evaluation 
F1 Errors that make a reading useless (due to the 
error, it is not possible to anticipate whether 
the measured blood glucose level is higher or 
lower than the true value and how great the 
deviation is). 
If only one of these errors is made, 
the result cannot be interpreted. The 
test must be repeated (correctly). 
F2 Errors that can lead to a false reading (or a 
false interpretation) in individual cases. 
The significance is dependent on 
the exact situation or the 
consequence that is drawn. 
F3 Errors that can have a negative effect on 
compliance. 
These errors have no impact on the 
measuring results, but possibly 
affect the willingness of the patient 
to perform the self-monitoring.72
F4 Errors that can make conducting the test more 
difficult or prevent it entirely (device 
components). 
Either the handling is unsatisfactory 
or the functionality is impaired. 
F5 Errors which make a consequential action / 
interpretation (by the patient, doctor, or 
pharmacist) more difficult. 
Readings not available for 
evaluation over the middle term. 
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Table 2. Potential sources of user-error. (Müller et al.86)
Potential sources of error Error 
code  
Cleaning hands F1 Blood 
sampling 
Drying hands F1 
 Inserting/changing  lancets F3 
 Adjusting the prick depth F3 
 Stimulating circulation (if needed) F3 
 Pricking of finger pad F3 
 Squeezing out the blood F1 
Strips Storage of strips F1 
 Expiration date of strips  F1 
 Use of the correct strips F1 
Glucometer Cleanliness of device and measuring cell F2 
 Settings (date, time) F5 
 Choice of unit (mmol/L, mg/dL) F2 
 Coding the device when changing to a new lot of strips (newer 
systems often do not require manual coding) 
F1 
Measurement Inserting the test strip/the disk F4 
 Applying the sample F2 
 Quantity of applied blood F2 
 Changing between different devices  
Other Saving/documenting the results F5 
 Check with glucose control material F1 
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Specificity of test strip enzymes
High specificity in enzyme activity, i.e. that the enzyme prefers glucose as a substrate and is 
not affected by the presence of other molecules, is a good prerequisite for its use in test strips. 
However none of the enzymes used are completely specific for glucose, and high 
concentrations of enzyme in the formula can make low side effects a real interference.59 As an 
example, the different forms of GDH are affected by maltose, mannose, galactose, lactose, or 
xylose in varying degrees. Most people do not have these sugars in their blood, however some 
drugs and rare diseases can lead to maltose, galactose or xylose being present, and if these 
patients use a GDH system they risk falsely high readings. A tragic example of this is reported 
by Kroll and Maher.87 Their case report describes a patient with insulin dependant type  
2 diabetes, who is admitted to the hospital for a thyroidectomy and who dies from 
hypoglycaemia due to falsely high glucose readings by a SMBG device used at the hospital. 
The patient was in treatment for end stage renal disease by continuous ambulatory peritoneal 
dialysis, and the dialysate used for this, isodextrin, is hydrolysed to maltose, thus leading to 
the high measurements and the wrongful administration of insulin to an already 
hypoglycaemic patient.87 Researchers in an American hospital found substances that interfere 
with GDH based glucometers in 1.2% of patients admitted over a 12 month period. Thirty six 
percent of those patients had an active order for an insulin product during the interference 
time interval, which means that they were dependant on SMBG measurements.88 To use a 
method based on GOD might seem the better choice, because while it is affected by mannose 
as well as 2- and 6-deoxyglucoses, neither of these are present in today’s medications. 
However, GOD’s natural second substrate is oxygen, which it reduces to hydrogen peroxide, 
and thus oxygen content of the sample may affect the result both in systems using oxygen as a 
mediator and those where another mediator is used.59 As it influences oxygen content, altitude 
can affect results.89 Other reducing substances may also interfere with the measurement such 
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as bilirubin, uric acid, ascorbic acid, paracetamol or dopamine.59;90 With the exception of 
paracetamol, these interferences are found when the plasma concentrations are well above the 
therapeutic level,90 however many diabetes patients develop renal impairment and failure, 
leading to unusually high plasma levels of drugs. Using mediators with low redox potentials 
reduces cross reactivity with other molecules and allows the measurement electrode to operate 
at a lower applied voltage which will reduce the interference and inaccuracy of 
electrochemical sensors.59
Enzyme activity is sensitive to temperature, as is the diffusion process and therefore most 
meters contain a temperature sensor and adjust the results accordingly. Still many meters are 
sensitive to differences in temperature between meter and strips.59;85
Hematocrit  
Earlier it was common that glucometers were calibrated to convert results to whole blood 
content, but as most clinical laboratory methods measure in plasma, this led to a great deal of 
confusion. Following a 2001 recommendation published by the International Federation of 
Clinical Chemistry that recommended all results being reported as plasma values,91 today, at 
least in Europe, most instruments show plasma values.72 The difference between plasma and 
whole blood glucose results85 is the result of plasma containing a higher percentage of water 
than erythrocytes do (approximately 93 % and 71 %, respectively), and because glucose is 
soluble in the water phase, there is a higher concentration of glucose in plasma then in whole 
blood. While SMBG is performed on whole blood, the meters measure the glucose content of 
the plasma fraction. A membrane in the strip does not allow red blood cells to enter the 
reagent layer where the enzymes are found (Figure 1). This should have eliminated the 
hematocrit-error from the results, but this is not always the case.85;92 While one is not sure of 
the reason for this, it has been suggested that it is because the blood cells block the pores in 
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the membrane, or because a high amount of blood cells limits the volume of plasma available. 
Another reason may be that a high hematocrit may alter blood viscosity and thereby decrease 
fluid permeability into the reagent layer.92   
HemoCue Glucose instruments measure the glucose content in whole blood, as a saponin in 
the cuvettes is used to hemolyze red blood cells so total glucose is determined.93 This would 
have reduced the error caused by hematocrit, but HemoCue instruments convert the measured 
value into corresponding plasma values by means of a fixed factor (1.11 91), thereby 
introducing the hematocrit error in the reported glucose result.  
Lot-to-lot variation 
Several studies have found that there may be significant lot to lot variation in glucometer test 
strips.73;76;85;94 Results varied with as much as 0.8 mmol/L between different lots of the same 
test strips when measuring capillary blood, and with as much as 1.3 mmol/L when measuring 
control material, differences that are clinically important at critical decision limits for 
glucose.76 Also, between-lot differences present in capillary blood can not necessarily be 
detected by the use of other control materials, as instruments that show little between-lot 
variation when using control material may still experience a significant between-lot variation 
when using capillary blood.76 It is therefore recommended that “manufacturers should be 
urged to produce more consistent glucose strips, and commutability studies should be carried 
out to ensure that control materials give valid results.”76
Cost of SMBG 
Substantial resources are spent on SMBG. It is difficult to find accurate and current 
worldwide figures, however an estimate from 2004 suggested that the cost was over 5 billion 
US dollars worldwide, with a yearly growth rate of 11.5 %.95 The American Diabetes 
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Association reported that the 2007 cost of diabetic supplies in USA was nearly 2 billion 
dollars.96 In 2008 Norwegian pharmacies sold test strips for more than 43 million Euros.97 In 
addition there are costs of lancets and of the glucometers themselves. Most glucometers are 
sold at low cost or given to patients free of charge by the manufacturers. Patients pay 
approximately 10 % of the total costs of blood glucose strips through a co-payment for each 
prescription, the remaining 90 % is covered by The Norwegian Social Insurance Scheme.98;99  
Research on cost-effectiveness100-107 faces the same problems as all effectiveness studies of 
SMBG do; namely that the clinical effect of SMBG relies on the patients using their SMBG 
results to modify treatment approaches or lifestyle.108 The limited amount of research done in 
this field mostly indicates that SMBG is cost effective.100;103-106;109-111 However, as this cost 
efficiency is based on assumptions of accurate measurements and compliant patients and as 
research shows this is not the case for many patients, perhaps a percentage of the total costs of 
SMBG should be directed towards SMBG education and follow-up of patients.72  
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The role of the pharmacist in the care of patients with diabetes  
Around the world community and hospital pharmacies are extending their focus from drug 
production and dispensing to a range of health care services.112 These include drug based 
services (e.g. medication reviews, dose adjustment);113-118 point of care testing (blood 
pressure, lipids, blood glucose, bone density),116;119-123 patient education and information 
services,114;119 and lifestyle adjustment services (smoking cessation classes, dieting 
classes)120;124;125. Several prescription-only drugs have been reclassified as OTC, such as the 
morning after pill, allergy medications and anti-obesity drugs, rendering the pharmacy 
employees with more responsibility for patient information. During the fall of 2009 
Norwegian pharmacists were given the right to prescribe influenza A medications following a 
severe increase of influenza A infections.126  
The concept of pharmaceutical care, introduced by Hepler and Strand in 1990 as a way of 
addressing the problem of medication related morbidity, is defined as “a patient-centred 
practice in which the practitioner assumes responsibility for the patient’s drug-related needs 
and is held responsible for this commitment”.127 Today, this model and others like it are being 
used by thousands of pharmacists across the world.128 Patients with diabetes are good 
candidates to receive such care, as diabetes is a disease that requires complex treatment 
regimes and follow-up, as well as a high degree of commitment from the patient.25 Studies on 
drug related problems (DRPs) in patients with type-2 diabetes have found an average number 
of DRPs from 1.2 (Norway)129 to  4.1 (Denmark)130 and 4.6 (Australia)131 per patient.  These 
included adverse reactions, dosing problems, interactions and non-adherence.129-131  
Diagnosed patients receiving drug treatment will visit the community pharmacy regularly, 
providing the pharmacists a unique opportunity to follow-up and discuss treatment and 
compliance.132 Therefore diabetes patients could benefit from the inclusion of a pharmacist in 
the team of health care workers committed to helping with disease management.29;133-135   
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The Norwegian pharmacy system 
The Norwegian pharmacy market is dominated by three pharmacy chains, Apotek 1 AS, 
Vitusapotek and Alliance apotek/Boots apotek, which by 1st of January 2010 fully owned 538 
of 629 privately owned pharmacies in Norway. In addition Norway has 33 hospital 
pharmacies owned by the Regional Health Authorities.136;137 The Norwegian pharmacy 
system went trough a radical change in 2001. New legislation allowed anyone (except 
pharmaceutical companies and prescribing physicians, veterinarians and dentists) to own 
pharmacies, provided that they employ a pharmacist holding a masters degree to run the 
pharmacy. Before 2001 Norwegian pharmacies were independently owned by certified 
pharmacists, and the number of pharmacies was strictly regulated.137;138 In January 2001 there 
were 397 pharmacies in Norway; in January 2010 the number was 662, an increase of 67%. 
While only 5 new pharmacies were established in the year 2000, approximately 30 new 
pharmacies have opened every year since.139 In 2009 Norwegian pharmacies dispensed over 
30 million prescriptions to 3.4 million different patients, i.e. 70 % of the Norwegian 
population. Including over the counter sales the pharmacies had 45.6 million customer visits 
in 2009.7;136;140 Most Norwegian patients with diabetes visit a pharmacy at least once every 
three months to collect prescription medication, as a three months supply is the set maximum 
amount the Norwegian social insurance scheme (NAV) will refund. 
Research on pharmacy services for patients with diabetes 
Many researchers have investigated the effects of diabetes care services in the pharmacy. 
Often the interventions are not a single defined service, but rather multifaceted comprehensive 
programs.121;134;141-152 The programs vary in content, but include services such as patient 
education, monitoring of blood glucose, blood pressure and lipids, medication reviews and/or 
adherence support. These report of significant improvements in HbA1c,121;141-144;146;148;149
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percentage of patients with HbA1c less than 7%,121;142;143;147;149 mean blood glucose141;150, 
blood pressure,121;134;143;144 percentage of patients who achieved target blood pressure (130/80 
mmHg),141;143 lipid levels,121;143;149 self-reported non-adherence145, drug-related problems,121  
as well as reductions in health care costs143;149, days of sick-time149 and estimated 10-year risk 
of coronary heart disease.144  
Studies have also been performed were the intervention was limited to a single service. 
Examples of interventions include group counselling,153 control of SMBG performance,86 and 
screening.154-157 Counselling showed a significant reduction in HbA1c that remained after 24 
months,153 while the SMBG controls halved the number of patients who made user errors.86
Methods of screening varied, from simple risk assessment using a tick-test (questionnaire), 
referring patients with one or more risk factors to their GP for diagnosis,156 to sequential 
methods starting with risk assessment, followed by measurement of plasma glucose for the at-
risk group before referral to GP for diagnosis.155;157 Krass et al compared the two methods and 
found significantly better costs efficiency and increased uptake of referrals to GPs in the 
group that received sequential screening.154
In spite of promising results when the studies are read individually, review studies point out 
methodological limitations. Blenkinsopp et al published a review of the effectiveness and 
acceptability of community pharmacy based services for patients with type 2 diabetes, but 
found too few studies in community pharmacy settings to make any general conclusions about 
effectiveness.119 In 2007 Machado et al158 published a systematic review/meta-analysis 
focusing on the sensitivity of patient outcomes to pharmacist interventions in diabetes 
management. They found that HbA1c is sensitive to pharmacist interventions, while fasting 
plasma glucose and systolic blood pressure were considered possibly sensitive. Lipid levels, 
adherence, knowledge and quality of life were considered probably not sensitive to 
pharmacists interventions. However the authors also point out that the quality of the literature 
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they have assessed can only be considered fair, mostly due to lack of blinding of patients and 
caregivers, and due to lack of reports of adverse drug events and adherence to interventions, 
and they argue that more research is needed to establish the association between intermediate 
and final health outcomes.158 This concurs with the results of a review of the effectiveness of 
pharmaceutical care looking at all patient groups, not only diabetes.159 It concludes that 
pharmaceutical care was effective in improving symptom management, medication use and 
surrogate endpoints such as blood pressure, HbA1c and cholesterol levels, but does not 
provide evidence supporting improved health related quality of life. The authors point out that 
greater consideration should be given to the outcome levels employed in the studies being 
done.159 A Cochrane study of the effects of extended pharmacy roles in general found that the 
research done supported the expanded roles of pharmacists in patient counselling but also 
points out flaws in study designs, and states that more rigorous research is needed to 
document the effects of outpatient pharmacist interventions.160  
Point of care tests (POCT) at the community pharmacy 
Point of care testing (POCT) is defined as “laboratory diagnostic testing performed close to 
the site of patient care, typically by clinical personnel whose primary training is not in the 
clinical laboratory sciences or by patients.”161 Point of care tests for glucose, HbA1c, lipids 
and blood pressure are part of the services being offered in several of the programs for 
diabetes care at community pharmacies around the world.116;120;148;162-164 The pharmacist as a 
provider of laboratory test results has been subject to much discussion,123;155;164-166 the main 
objections being that pharmacy employees are not trained to perform POCTs, and that over-
utilization and inappropriate test utilization can lead to significant increases in cost of care.161
It has been pointed out that while performing POCT may seem simple, it can be difficult to 
comprehend the complexity of the testing process and the many variables that can affect the 
test results.167 Those who are positive to pharmacies providing POCTs argue that pharmacists 
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“may represent an additional point of choice and access to health care, potentially reducing 
the number of journeys (patients) have to undertake”.164
The following should be considered before introducing POCT to the pharmacy setting: 
• Why should the tests be performed in the pharmacy? 
• How are the results going to be used? 
• How to educate the pharmacy staff in laboratory testing 
• How to educate the pharmacy staff in counselling patients on the results of the tests 
• How to ensure best possible quality of the instruments and measurements  
• How to convey the result to the patients’ general practitioner (GP) 
Performing high quality POCT tests requires staff training and competency, method 
validation, and ongoing comparison with core laboratory results. An appropriate record trail 
should be maintained (linking operator and his/her training/competency with device 
validation/maintenance/quality control). Dedicated resources and multidisciplinary 
commitment and cooperation are necessary to ensure the highest quality services.161;168  
The choice of POCT instrument used in the pharmacy should rely on the purpose of the tests.  
For example, though glucometers for SMBG may obtain measurements of sufficient quality to 
monitor the progression of a single patient’s disease, the maximum allowed total error of 20 
% means that these devices are not suited to diagnose diabetes. Also, though instruments may 
be easy to use, they still require a quality assurance regime and the person performing the test 
must be trained in the instrument’s use and quality assurance. The intended use of the results 
will also dictate the procedures for information provided to the patient and potentially to his 
or her GP. If the tests are intended as an ongoing monitoring of the disease and effects of 
medication, it is essential that this is agreed upon beforehand with the patient’s GP and that 
the GP receives a copy of the results to avoid unnecessary double tests and costs, and also to 
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avoid confusion if the patient receives deviating results from his GP and his pharmacist.  If 
the test is intended to identify people at risk of having diabetes, the pharmacy should use 
equipment suited for this purpose, have strict guidelines for what value constitutes risk and 
how to follow-up patients at risk to ensure that they visit their GP for diagnosis and 
potentially treatment. Careful consideration must be given on how to relay information about 
risk to patients to facilitate that these contact their GP, but at the same time avoid unnecessary 
anxiety.   
A few years ago it became possible to buy self-tests for a long list of ailments from 
community pharmacies, from Chlamydia and urinary tract infections to allergies and celiac 
disease. However, especially the Chlamydia test was widely criticised for being of poor 
quality and today many of these products have been withdrawn from the pharmacies.169
While it may be temping for health personnel and patients both to perform tests “because  we 
can” it is important from both a health cost view and a public health view that only tests with 
a clear purpose are performed, and that the pharmacies can document the quality of tests they 
provide and of the self-tests they sell. The new pharmacy contract in England lets the patient’s 
GP delegate tasks to the pharmacy, and this ensures that the GP gets to keep the coordinator 
role and overview over the patients’ treatment and follow-up. However, there is no regulation 
of POCT, and this, it has been stated, “underlines the central role for established NHS 
professionals in developing suitable frameworks on behalf of primary care”.164 In Norway, the 
Norwegian Quality Improvement of Primary Care Laboratories (NOKLUS) has begun this 
work by ensuring support and influencing guidelines for laboratory tests performed in primary 
care, mainly aimed at GPs’ offices, but also in nursing homes. If the pharmacies are to 
perform POCTs they should also be enrolled in NOKLUS’ systems for quality assurance. 
Before we begun the studies that this thesis is comprised of, little was known of the extent of 
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pharmacy services offered to diabetes patients in Norway, the extent of POCT tests being 
performed, and the quality of tests performed at the pharmacy. 
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Aims of the thesis 
• To describe Norwegian pharmacies’ involvement in diabetes care, explore 
pharmacists’ views on future services and investigate whether the recommendations in 
the Norwegian diabetes declaration for pharmacies have been implemented (Paper I). 
• To implement a method for glucose measurement at community pharmacies, and to 
evaluate if it is sufficiently accurate and precise to be used as a comparison method for 
controlling patients’ self-monitoring of blood glucose. Also to investigate whether the 
pharmacies can achieve glucose measurements of comparable analytical quality to 
those performed at general practitioners offices. (Paper II). 
• To evaluate the analytical quality of Norwegian diabetes patients’ SMBG 
measurements as well as the frequency of user errors among the diabetes patients by 
performing a control of this at the community pharmacy, to investigate whether these 
pharmacy controls together with a program for quality assurance improve the quality 
of the measurements and explore the views of the patients on receiving such a service 
at their community pharmacy (Paper III).  
• To use nationwide data from 2008 to determine the prevalence of self-monitoring of 
blood glucose among all non-institutionalized persons living in Norway, estimate the 
prevalence of SMBG among diabetes patients, the frequency and cost of SMBG and 
the use of different types of strips (Paper IV). 
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Summery of papers 
Paper I. Diabetes care in Norwegian pharmacies: a descriptive study.  
Kjome, RLS, Sandberg, S and Granas, AG. Pharm World Sci 2008 30:191-198. 
Objective: To describe Norwegian pharmacies’ involvement in diabetes care, to investigate 
pharmacists’ views on future services and to investigate whether the recommendations in the 
Norwegian diabetes declaration for pharmacies have been implemented.  
Setting: Hospital and community pharmacies in Norway 
Method: All 543 pharmacies in Norway, 511 community pharmacies and 32 hospital 
pharmacies, were sent a link to a web-based questionnaire. One pharmacist from each 
pharmacy was asked to complete the questionnaire. The questionnaire covered subjects from 
the diabetes declaration and the pharmacists’ views on which services the pharmacy should 
offer in the future as well as demographic characteristics.  
Results: In total 358 (66%) pharmacists completed the questionnaire. The diabetes declaration 
was read by 37 % of the pharmacists. Nearly all pharmacies followed the declarations’ 
recommendations in regard to glucose monitoring services. Twenty four percent of the 
pharmacies offered medication reviews, and about 10 % offered screening for undiagnosed 
diabetes. Counselling on lifestyle issues was the recommendation that was least implemented.  
Eighty one percent of the pharmacists reported that they wished to expand their services 
towards people with diabetes. Services in regard to glucose monitoring scored the highest, but 
the views on offering a variety of future services varied a great deal. Already performing a 
service increased the chance of the pharmacist being positive towards offering it. 
Conclusion: Norwegian pharmacists report that they are involved in a wide range of diabetes 
services, even though only 37 % have read the diabetes declaration. The pharmacists wish to 
be active in supporting patients with diabetes, and further research should concentrate on 
identifying the areas where the effect of their involvement is the greatest. 
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Paper II. Implementation of a method for glucose measurements in 
community pharmacies. 
Kjome, RLS,  Nerhus, K and Sandberg, S. Int J Pharm Pract 2010;18(1):13-19. 
Objectives: This study aimed to implement a method for glucose measurements that could be 
used as a comparison method for controlling patients’ self-monitoring of blood glucose. 
Further we wished to investigate whether the pharmacies could achieve an analytical quality 
comparable to glucose measurements performed at general practitioner offices. 
Setting: Sixteen community pharmacies in Norway. 
Method: Sixteen pharmacy employees were trained in glucose measurement, quality control, 
and blood sampling. The comparison method, HemoCue Glucose 201+, was validated in four 
steps: 1) estimation of the variation between the HemoCue instruments to be used at the 16 
pharmacies, 2) comparison between the results from HemoCue and the results of a laboratory 
glucose method, 3) monitoring the quality of HemoCue by use of internal quality controls and 
4) participation in an external quality assessment scheme. The pharmacies’ results of the 
external quality assessment were compared to those of 359 general practitioners’’ offices. 
Main outcome measures: Variation among HemoCue instruments, quality of Hemocue 
instruments compared to a laboratory method, number of pharmacies achieving measurements 
of acceptable precision and trueness. 
Results: An assessment of the imprecision and bias of the HemoCue instruments showed that 
the coefficient of variation was 6.1% in the low level, 1.7 % in the normal and high levels, 
and that negligible bias was present in the normal level. The coefficients of variation for 
internal quality controls were 4.5%, 1.5%, and 1.2% for the low, normal, and high levels, 
respectively. All pharmacies achieved good precision and acceptable or good trueness in the 
external quality assessment. The pharmacies exhibited significantly lower variation between 
sites (2.2% and 1.2%) than general practitioners’ offices (3.8% and 2.9%) on both external 
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quality assessment samples. 
Conclusions: Given correct training and the establishment of a system of quality assurance, 
pharmacies are capable of obtaining glucose measurements that can be used as comparison 
measurements for controlling patients’ meters. The pharmacies had external quality 
assessment results comparable to general practitioners’ offices. 
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Paper III. Quality assessment of patients' self-monitoring of blood 
glucose in community pharmacies  
Kjome, RLS, Granas, AG, Nerhus, K and Sandberg, S. Pharmacy Practice (internet) 2010; 
8(1):62-69. 
Objective: Diabetes patients’ self-monitoring of blood glucose was evaluated using a 
community pharmacy-based quality assurance procedure. We investigated whether the 
procedure improved the quality or the patient performance of self monitoring of blood 
glucose. The opinions of the patients taking part in the study were examined.  
Setting: Sixteen community pharmacies in Norway.  
Method: The results of patient measurements were compared to the results obtained with 
HemoCue Glucose 201+ by pharmacy employees in 16 community pharmacies. Patient 
performance was monitored using an eight item checklist. Patients whose measurements 
differed from pharmacy measurements by more than 20% were instructed in the correct use of 
their glucometer. The patients then re-measured their glucose. If the results were still outside 
the limits, the control procedure was repeated with a new lot of glucometer strips, and then 
with a new glucometer. The patients returned to the pharmacy for a follow-up visit after three 
months.  
Main outcome measures: Number of patients whose measurements deviated from pharmacy 
values by more than 20 % and number of user errors.  
Results: During the first visit, 5% of the 338 patients had measurements that deviated from 
pharmacy values by more than 20% and user errors were observed for 50% of patients. At the 
second visit, there was no significant change in the analytical quality of patient measurements, 
but the percentage of patients who made errors had decreased to 29% (p < 0.001). Fifty-one 
percent of the patients reported a greater trust in their measurements after the second visit. 
Eighty percent of patients wished to have their measurements assessed yearly. Of these 
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patients, 83% preferred to have the assessment done at the community pharmacy.  
Conclusion: A community pharmacy-based quality assurance procedure of patients’ self 
monitoring of blood glucose improved patients' confidence in their measurements and 
significantly reduced the number of user errors. The analytical quality of the measurements 
was good and did not improve during the study. The high analytical quality might be 
explained by a selection bias of patients participating in the study. 
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Paper IV. The prevalence of self-monitoring of blood glucose and costs 
of glucometer strips in a nationwide cohort 
Kjome, RLS, Granas, AG, Nerhus, K, Roraas, TH and Sandberg, S. (2010, submitted). 
Objective: To use nationwide data to determine the prevalence of SMBG among all non-
institutionalized persons living in Norway, estimate the prevalence of SMBG among diabetes 
patients, the frequency and cost of SMBG and the use of different glucometers.  
Methods: This retrospective, descriptive study is based on data of sales of glucometer strips to 
non-institutionalized persons in Norway in 2008. The data included: gender, age group, month 
of purchase, sales-place, type of strips, number of packages dispensed and cost of strips. 
Additionally, statistics on sales of insulin and oral anti-diabetics were obtained from the 
Norwegian prescription database. 
Results: A total of 96,999 persons purchased strips, a prevalence of 2 %. Approximately 70 % 
of diabetes patients practice SMBG. Average patients used 1.7 strips per day, and younger 
patients purchased more strips than older patients. Less than 50% of patients perform glucose 
measurements daily. One percent of patients used more than 10 strips daily and was 
accountable for eight percent of total costs. Most patients use only one type of strips, but 
number of purchased strips increased with number of different strips. The average annual cost 
of strips was 446 € per person.  
Conclusions:  Two percent of all non-institutionalized inhabitants and an estimated 70 % of 
patients using diabetes medication purchases SMBG strips. A small percentage of the patients 
use a substantial proportion of the costs. This, along with the fact that over half of the patients 
monitor less than once per day, calls for tighter follow-up of the patients. 
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Methodological considerations
The empirical data of this thesis was collected using different methodologies described in 
detail in the separate papers. Table 3 gives an overview over design and data collection used. 
In the following methodological considerations will be further discussed. 
Table 3. Methodological overview over the papers included the thesis
Paper Design Data collection Study population 
I Descriptive study Electronic questionnaire  One pharmacist 
from each of 358 
Norwegian 
pharmacies 
II Methodological 
study 
Results of the pharmacies internal and 
external quality controls, results of GPs’ 
external quality controls 
16 employees from 
16 community 
pharmacies, 
359 GP offices using 
HemoCue Glucose 
201+ 
III Before and after 
study 
Structured patient interviews before the 
first and after the second pharmacy visit, 
results of pharmacy and patient glucose 
measurements at the first and second visit, 
registered user errors at the first and 
second visit 
338 diabetes patients 
at the first visit, 308 
patients returned for 
a second visit 
IV Non-experimental 
database study 
Data received from the Norwegian health 
economics administration on sale of 
glucometer strips 
The 96999 patients 
who purchased 
glucometer strips in 
Norway in 2008 
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Diabetes care in Norwegian pharmacies (Paper I) 
Internal validity 
Validity refers to the degree data or results are correct or true.170 A finding is not simply valid 
or invalid, but will have some degree of validity for a stated purpose.171 In this descriptive 
study we increased the face and content validity of the questionnaire by performing initial 
interviews with pharmacy employees engaged in diabetes work, and by using a pilot group to 
ensure that the questions were easy to understand and that the reply categories were relevant 
and extensive.172 A validity limitation is that we did not observe the practice of the 
pharmacists. We can only report what the pharmacists state to do, not what they actually do. 
The questions inquiring about how often pharmacists provided counselling or referred patients 
to other health care professionals cannot be used to quantify frequency. While one pharmacist 
might rate once a week as often, another might rate once a month as often. However the 
answers can be used as internal ranking of frequency between different types of counselling. 
The same applies for the items concerning views on future pharmacy services.  
External validity 
It is always essential to consider whether results also apply to those outside of a study 
population.173 In our study, we were in a unique situation as we could include Norwegian 
pharmacies in the study population. Still, our results might not be valid for all Norwegian 
pharmacies due to response bias.  The one pharmacist most engaged in diabetes activities in 
each pharmacy filled in the questionnaire and their views may differ from those of the rest of 
the pharmacists working in the pharmacy. Likewise, due to differences between countries in 
pharmacy ownership structure, policy, legislation and practice, our results may be 
transferrable to some, but not all other countries.
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Quality assurance of patients' self-monitoring of blood glucose in 
community pharmacies (Papers II and III) 
Internal validity 
The validity of the glucose measurements performed at the pharmacy was a main focus of our 
research, and is described in detail Paper 2. The main conclusion is that the pharmacies 
achieved glucose measurements of good precision and trueness.   
In our study we chose to use the ISO limits of ± 20 % deviation for acceptable performance. 
In the paper “Quality Assurance of Self-monitoring of Blood Glucose at the General 
Practitioner's Office”, it is suggested that one might adjust these limits based on the method 
bias as compared to the laboratory reference method.174  One way of doing this is to correct 
the pharmacy values using a linear correction formula derived from a linear regression 
between the pharmacy method (HemoCue Glucose 201+) and the reference method (Architect 
ci8200), and then adding the 20 % limits (see Appendix 4). When applying this to our results 
from the first patient visits, it did not affect the number of analytically unacceptable 
measurements (Appendix 4). An alternative way to set quality specifications is to use the 
Clarke Error Grid Analysis described in the introduction. If we were to use this on the 
patients’ results, only one patient’s measurement would have been considered unacceptable 
(see Appendix 5).    
When we were planning the study it was presumed that the checklist items were fairly 
intuitive (such as “are strips expired?” and “does the patient use a big enough drop of 
blood?”). Therefore we did not test intra- or inter-tester reliability. In hindsight such tests 
would have ensured a higher reliability of the registration of patient errors, as some of the 
items on the checklist might have left room for interpretation. However, the items on the 
checklist were carefully explained during the training of the pharmacy employees, and careful 
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instructions were given with regard to the meaning of each item (e.g. “Unsatisfactory 
sampling” would encompass not changing the lancet, pricking in the middle of the finger pad 
where there are most nerve endings or squeezing out blood). Also, all the lists were reviewed 
and compared to the instrument in question’s user manual, to ensure for example that in 
instruments that did not require coding, lack of coding was not registered as an error. The 
focus on user error at the course day, the fact that all pharmacy employees received the same 
training shortly before seeing patients and the thorough review of the completed checklists 
strengthened the reliability. If one was to repeat this study, it would be beneficial to use a 
more detailed checklist, similar to the one published by Müller et al86 to make it easier to 
interpret the results. 
Before the first and after the second visit patients were interviewed about their SMBG habits 
and their views on participating in the study. We chose to let the employees question the 
patients to reduce the chance for unanswered questions and to allow for clarification of 
questions and answers.175 Since all employees were given the same instructions this should 
strengthen the reliability of the responses. However there is the issue of recall bias for the 
questions where the patients were required to remember when they started SMBG and any 
training they received. Recall bias is also relevant where patients reported HbA1c values. 
Also patients’ reported service satisfaction may be overstated because the responders answer 
what they think the interviewer wants to hear175 and exaggerate how positive they are because 
the response was not anonymous.
Perhaps the most serious limitation is that our power calculations were based on the 
assumption that at baseline approximately 15 % of the participating patients would have 
glucose results that deviated by more than 20 % from the pharmacies’ results, but among our 
patients only 5 % had analytically unacceptable results. Hence we could not determine 
whether our interventions had any effect, nor could we establish whether background 
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variables such as gender, age, HbA1c or instrument could predict poor measurements. The 
assumption of 15 % poor measurements at the first visit was based on previous studies that 
found from 9-16 % of patients’ results deviated by more than 20 %.80;82;174 One explanation is 
that current glucometers are less affected by user error, but we believe that our results reflect a 
patient selection bias.  
External validity   
The pharmacies participating in our study all achieved good quality of the measurements they 
performed. All were from a single pharmacy chain, and therefore we can not with certainty 
say that the results are applicable to all Norwegian pharmacies. However there are no clear 
differences between the pharmacy chains that imply that they are not. Still, in the participating 
pharmacies the project was prioritized by giving the employees responsible time away from 
regular tasks for training; and necessary resources for this, for enrolment in NOKLUS and for 
necessary equipment was provided by the pharmacy chain. If these factors are in place other 
Norwegian pharmacies should be able to achieve the same quality of measurements. The 
number of employees and size of the pharmacy may be of more significance than chain 
affiliation, as it may be difficult for the smaller pharmacies with few employees to clear time 
from the pharmacy’s routine tasks to receive training and implement the necessary quality 
control systems. The quality of measurements performed by GP offices that partake in the 
NOKLUS EQAS have shown improvement over time176, and this could perhaps be expected 
from the pharmacies as well, as they become more experienced with the control procedure 
and receive feedback from NOKLUS.  
Regarding the results of the patients, it is unlikely that these are representative for all 
Norwegian diabetes patients. All studies where patients volunteer to participate will be 
affected by some selection bias, and our results lead us to believe that this has been quite 
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pronounced in our sample, with the most motivated patients accepting the invitation to 
participate. Patients less interested in SMBG, those who regard it as uncomplicated or those 
who felt unsure and did not wish to have their performance appraised may have been less 
inclined to volunteer. The recommended HbA1c value for patients with diabetes is below 
7%,177 and the mean reported value of our patients was 7.1%, which also indicates that these 
patients are well regulated. Also, while results from paper IV found that only 45 % of persons 
who purchased SMBG strips bought enough to perform daily measurements, 63 % of the 
patients in our study replied that they monitored their blood glucose once daily or more 
(unpublished results, se Appendix 6), and this may imply that the patients participating in our 
study are more compliant than the average SMBG user. This is problematic because it means 
that we have not managed to recruit the patients who would have benefitted the most from our 
intervention. If the study population had been different, for instance diabetes patients chosen 
by GPs based on high HbA1c levels, we might have seen different results of patients’ 
measurements at baseline.  
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The prevalence of self-monitoring of blood glucose and costs of 
glucometer strips in a nationwide cohort (Paper IV)
Internal validity 
The validity our nationwide data describing the number of patients who practice SMBG and 
total prevalence of SMBG is high; as we have data on all sales of strips to non-
institutionalized persons in Norway, and it is unlikely that people who purchase strips do not 
practice SMBG at all. However, while the numbers we find are valid in terms of purchase, 
patients will not necessarily use all the strips they buy, thus our estimated frequency of 
SMBG may be too high. The estimated proportion of patients using diabetes medication who 
practice SMBG is also uncertain, because we only have national data and not person specific 
data for the patients who use diabetes medication. Thus, theoretically these can be different 
people than those who purchased strips. Also, some of the medications may have be have 
been used for other indications than diabetes. 
External validity 
Our results should be valid for all persons practicing SMBG in Norway. However, SMBG 
habits may change in the population over time. In 2009, new Norwegian guidelines for the 
diagnosis and treatment of diabetes were introduced, and though these do not recommend a 
certain SMBG frequency, they may influence the clinicians’ attitudes and thereby also the 
patients’ practice. Our results can most likely not be applied to populations where patients are 
required to pay in whole for their own strips, but one could assume that the results would be 
similar in countries such as Sweden, Finland and Denmark, where reimbursement systems are 
similar. However, this will also depend on national guidelines with regard to SMBG. 
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Discussion of results 
Self-monitoring of blood glucose is an important aspect of diabetes management for many 
patients. Nearly one hundred thousand Norwegians purchased glucometer strips in 2008, and 
more than 43 million Euros was spent on strips.97 Still, education of patients in the correct 
way of performing SMBG and follow-up of the measurements performed by patients is not 
routinely done. In paper III we found that 44 % of the patients had not received any training in 
SMBG. This concurs with Skeie et al’s findings from 2002, where 47 % of the patients 
interviewed in general practice and 56 % of hospital out-patients stated that they were self-
educated.73 Seventy-eight percent of the 338 patients visiting the pharmacies for an SMBG 
assessment stated that they never checked if their device showed the correct result (results not 
published, see Appendix 6), while in Skeie’s study 63 % stated the same.73  
It is the physician who prescribes SMBG who is responsible for ensuring that the patient is 
taught how to and when to perform SMBG and how to make use of the results. The physician 
is also responsible for the amounts of strips that are prescribed. The findings from paper IV 
confirm that there is both over-and underuse of SMBG strips in different sub-groups of 
patients. In Norway it is common that the prescribing physician writes “Equipment for three 
months use of SMBG” (or for a year) on the prescription. In practice, this means there are no 
limits to the amount of strips that the patient can collect during that period. Good guidelines 
on SMBG frequency are lacking, and with the great variety of equipment on the market today, 
some prescribers might find it difficult to advise patients on this. Barber’s model for good 
prescribing states that the prescriber should have four aims: to maximize effectiveness, to 
minimize risks, to minimize costs and to respect the patient’s choices (see Figure 4).178 These 
aims will often have to be balanced against each other: The patient should monitor often 
enough to be able to adjust medications, diet and exercise so that he avoids hypo- or hyper 
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glycemia, but still limit the amount of SMBG, as it is an invasive procedure that involves 
pain/discomfort. The prescriber should aim to respect the patient’s autonomy regarding the 
necessary frequency of monitoring, while at the same time considering the costs that it 
involves. The prescriber should come to an agreement with the patient on a maximum yearly 
use of strips given a sensible testing frequency, depending on the patient’s medication regime 
(insulin or not) and on how well regulated the patient’s diabetes is. If the patient for some 
reason needs more than the agreed amount, he would have to contact the physician, who then 
can decide whether further follow-up or therapy adjustment is necessary. 
Figure 4. Aims of good prescribing – and their most common conflicts. (Barber178) 
In paper IV we found that there was a small group of patients who bought more than 5000 
strips per year, i.e. these patients bought enough strips to be able to perform SMBG more than 
13 times per day, every day, throughout the year. One would assume that if the prescriber 
knew that a patient collected 5000 strips during one year they would find it imperative to 
discuss the issue with the patient. However, when no maximum amount of strips are indicated 
on the prescription, it is difficult for the dispensing pharmacist to infer if and when they 
should contact the prescriber concerning patients who have a high consumption of strips. 
49 
Also, a patient may collect strips from several different pharmacies, and a pharmacist will 
only have a full account of the strips dispensed at his or her pharmacy. Therefore the 
prescriber has no way of knowing how many strips the patient uses unless he/she chooses to 
ask the patient. A Norwegian diabetes register, based on consent from diabetes patients and 
physicians, is under implementation. As a part of this the physicians will be asked to enter 
patients’ SMBG frequency. This may act as a reminder for the physician to address the topic 
of SMBG frequency, and the feed-back physicians receive from the register comparing results 
of their patients to national and regional mean frequencies may be helpful in uncovering over-
and under utilization of SMBG.  
An older patient group, more complex treatment regimes, and focus on treating more patients 
in primary healthcare has lead to a growing workload for Norwegian GPs.179 Educating 
patients in SMBG and following up on their measurements and strips use could be among the 
tasks GPs delegate to pharmacies. A report commissioned by the Ministry of Health and Care 
Services and provided by The Directorate of Health, “Medical help in pharmacies” lists 
“Follow-up of patients with diabetes” as one of the initiatives that have been seen to have an 
effect in international studies of new pharmacy services, especially patient education, 
guidance in the correct use of drugs and diabetes equipment and systematic follow-up of 
diabetes patients with feed-back to the patient’s GP. The work group behind the report 
concludes that Norwegian pharmacies would be suited to provide 1) technical guidance in the 
use of SMBG equipment, 2) guidance in the use of other medical equipment and 3) 
identification of persons with unidentified type 2 diabetes or at high risk of developing type 2 
diabetes by use of a diabetes risk questionnaire. They point out that while it is common 
practice in pharmacies to provide advice on use of SMBG equipment, formal agreements 
defining what information should be given is lacking, and advice that the services should be 
standardized.   
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The findings in Paper I confirm that Norwegian pharmacies offer SMBG support in the form 
of help in choice of glucometer and SMBG training, and also that half the pharmacies offer to 
assess patients’ measurements. However, most pharmacies did not have standardized 
operating procedures describing what the services should include nor quality control systems 
in place for these services.180 To gain maximum benefit from such a service, the role of the 
pharmacy in patient SMBG education should be agreed upon with the GP, and the content of 
the service should be standardized so patients receive the same care independently of where 
they live or which pharmacy they choose to use. In a paper by Johnson investigating the 
pharmacist’s role as a diabetes educator, the author suggested elements in pharmacy-provided 
SMBG education. He recommended that pharmacists should explain the benefits of SMBG 
and give instructions on how to use the glucometer (knowledge). Using a new device could 
then be demonstrated to the patients (vicarious experience), followed by providing time for 
the patients to use the meter themselves (performance accomplishment). The pharmacist 
should offer encouragement (verbal persuasion), and lastly, patients should feel they are in a 
relaxed environment.181   In addition we would add that pharmacies that offer control 
measurements to check the patient’s glucometer should implement quality control procedures 
such as those we have described in Paper II, to ensure the trueness and precision of the 
measurements they provide. There should also be a feed-back system so the patient’s GP can 
be informed if alarming glucose values or other patient needs that require physician follow-up 
are uncovered.  
The results in Paper I show that the pharmacists wish to provide this type of service. The 
responding pharmacists strongly agreed that pharmacies should offer to assess patients’ 
SMBG measurements. We also asked the 16 pharmacy employees who participated in our 
second study (paper II and III), to evaluate the service after completing all patient visits. A 
summary of their replies (not published) can be found in Appendix 7. Overall the satisfaction 
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with training and execution of the study was high, and they all wished to continue the SMBG 
service at their pharmacies. In a Dutch study on community pharmacies’ involvement in 
SMBG support for patients with diabetes, they found that the provision of SMBG services 
varied greatly between pharmacies, but those who were involved in local agreements with 
other healthcare professionals provided more SMBG services. The authors concluded that 
even though practice guidelines exist, pharmacists are likely to form their role definition 
based on self-derived norms, leading to a wide range of professional behaviour. As patient 
counselling is a relatively new activity compared with technical processes, there is a lower 
threshold for pharmacists to get involved in SMBG calibration/checking.182  This could to 
some degree explain the higher interest of the Norwegian pharmacists in SMBG related 
activities compared to participating in activities such as dieting courses.180  
When we offered our SMBG assessment service to pharmacy customers (Paper III) our results 
lead us to believe that we did not recruit the less motivated patients. It might be advantageous 
to make both an introductory SMBG education session and follow-up yearly or semi-yearly 
SMBG assessments mandatory for all patients collecting SMBG equipment, but it is difficult 
to recommend such an extensive intervention based on our results, as they show the quality of 
the patients measurements to be good. On the other hand, finding that the quality is 
satisfactory at one point in time does not mean that later quality control is unnecessary. One 
could envision implementing mandatory assessments of patients’ SMBG as well as their use 
of strips as a test project over for instance two years. This would be a way to ensure that the 
money used on SMBG was well spent, and would also give access to some very interesting 
data about the quality of glucometers in the hands of the patients. A cost-benefit analysis 
would be an important aspect of such a test project, and one could then investigate different 
reimbursement alternatives, e.g. including the cost of the service in the cost of the strips, or 
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reimbursing the pharmacies with a fee for providing the service itself, similar to the way they 
were reimbursed when pharmacists prescribed influenza medication.126    
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Implications for pharmacy practice and future perspectives  
The findings of this thesis indicate that there is a need for better education and follow up of 
diabetes patients’ SMBG, that Norwegian pharmacies are offering SMBG related services to 
diabetes patients, and that while proper quality control of the services may have been lacking 
in the past, pharmacies were capable of performing good quality POCTs when enrolled in 
NOKLUS’ EQA scheme.  
All pharmacies that offer to perform tests should be required to have the necessary quality 
control measures in place, and purchasing such services from NOKLUS would most likely 
lead to a continuing improvement of the quality of tests being performed, similar to what has 
been seen for laboratory tests performed at GPs offices.176 Unfortunately, the steering group 
of NOKLUS, will only allow pharmacies to enrol under the condition that they agree not to 
perform any type of diabetes screening, a pharmacy service the Norwegian medical 
association is strongly opposed to. As the pharmacies would not agree to this, they now 
perform blood glucose measurements, but without access to the best available method for 
quality assessment of the measurements they perform. This is not favourable for pharmacies 
or patients. It is important to have an open discussion about where one would achieve the best 
effect of pharmacies’ involvement in diabetes care, with the ultimate goal of ensuring the best 
possible care for patients with diabetes and also the best possible use of health resources.   
Future studies involving diabetes care at the pharmacy should focus on uncovering more 
information on how patients’ use SMBG results, how to help them use their results 
correctly,72  as well as finding the ideal frequency of measurements. Identification of patient 
groups in special need of follow up could ensure a better outcome of interventions. It would 
be useful to include cost-benefit analysis in all studies of pharmacy services in order to better 
be able to identify where the time of the pharmacist is best spent. 
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Conclusions 
• As a group Norwegian pharmacies offer a broad range of services for patients with 
diabetes, however the services offered vary greatly between pharmacies. The 
Norwegian diabetes declaration has not been successfully distributed and integrated 
into the pharmacies’ routines, but the pharmacies have implemented several of its 
recommendations. The pharmacists wish to expand their services directed towards 
diabetes patients, and are especially positive to services regarding SMBG and 
medication counselling. (Paper I.) 
• When given adequate training, follow-up and equipment pharmacy employees can 
achieve glucose results that are precise and accurate enough to be used as target values 
for patient SMBG results, comparable to those achieved at GPs’ offices. (Paper II.) 
• Amongst the patients participating in our study, 95 % achieved SMBG results that 
deviated from the comparison method by less than 20 %, however 50 % of the patients 
made one or more user errors. After visiting the pharmacy for a SMBG performance 
assessment, the number of user errors was significantly reduced and the patients 
reported more confidence in their results, yet the analytical quality of the 
measurements was unchanged. Eighty percent of the patients wished to attend such a 
service yearly and of these 83 % preferred the community pharmacy as the site for 
such a service. (PaperIII.) 
• In 2008 the prevalence of SMBG in the non-institutionalized Norwegian population 
was 2 %, while approximately 70 % of medically treated diabetes patients purchased 
strips. One percent of the buyers purchase enough strips to perform 10 or more 
measurements per day, while 45 % purchase enough to perform daily measurements. 
Number of purchased strips increased with the number of different types of strips 
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purchased. Total cost of glucometer strips was 43,250,681 €, an average of 446 € per 
person. (Paper IV.)  
The sum of this work suggests that Norwegian pharmacies can be more actively used in 
assisting diabetes patients with their SMBG. The employees are motivated, and already 
involved at a smaller scale. Given correct training and follow-up they are capable of 
performing services involving point-of-care tests of good analytical quality, and patients are 
happy to receive this type of service from their community pharmacy. A small number of 
patients use a disproportionately large amount of the resources spent on SMBG, while a large 
number of patients rarely perform SMBG, giving room for improvement in the way these 
resources are being spent.  
Challenges that remain are creating multidisciplinary agreements on the provision of SMBG 
education and follow-up, uncovering how to reach the patients that are in most need of 
assistance, attaining access for pharmacies to the quality control support from the Norwegian 
Quality Improvement of Primary Care Laboratories, and ensuring remuneration for the 
services. 
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